Pharmaceutical companies Moderna and Merck released detailed Phase 3 results on October 22, 2026, showing that their investigational mRNA cancer therapy, combined with the immunotherapy drug Keytruda, reduced the relative risk of recurrence or death by 42% in patients with high-risk melanoma compared to Keytruda alone. The companies published the findings from the INTerpath-001 study early after data leaked on social media ahead of a scheduled presentation at the European Society for Medical Oncology (ESMO) Congress 2026, according to Scientific American and Fierce Biotech.

The global study followed 1,137 patients whose stage IIB through IV melanoma tumors had been completely removed by surgery, according to Merck. After a median follow-up of 24.6 months, adding the customized mRNA injection—known scientifically as intismeran autogene (V940 or mRNA-4157)—to standard pembrolizumab (Keytruda) therapy also lowered the relative risk of the cancer spreading to distant organs or causing death by 38%.

The findings have been accepted for publication in The New England Journal of Medicine, and both companies confirmed they are now engaging with regulatory authorities regarding potential approval. Despite meeting its primary goals, the announcement was accompanied by a 26% drop in Moderna's share price, as noted by The Chosun Daily, as investors and analysts weighed the timeline of the benefits and the remaining clinical questions.

Breaking Down the Numbers: Relative vs. Absolute Risk

In oncology studies, understanding how risk reductions are calculated helps clarify what the treatment achieves in practice. While the headline figure highlights a 42% reduction in the risk of recurrence or death (a hazard ratio of 0.58), this represents a relative risk reduction over time rather than a 42-percentage-point jump in the total number of recurrence-free patients.

According to Reuters and the American Journal of Managed Care, the two-year recurrence-free survival rate was 82.2% for patients receiving both the mRNA therapy and Keytruda, compared with 70.0% for those receiving Keytruda plus a placebo. This translates to an absolute difference of roughly 12.2 percentage points at the two-year mark.

A similar pattern emerged for distant metastasis-free survival, which measures whether the cancer spreads to parts of the body far from the original tumor site. Across the entire study period, the combination cut the relative hazard of distant spread or death by 38% (a hazard ratio of 0.62). At the two-year mark, 88.5% of patients in the combination group remained free of distant metastasis. For the Keytruda-only control group, The Boston Globe reports the two-year rate at 80.2%, while other secondary reports, including Fierce Biotech, round the control figure to 80.0%.

How the Personalized Therapy Works and Why Timing Matters

Unlike traditional preventive vaccines—such as those for measles or human papillomavirus (HPV), which are given to healthy people to prevent infection—intismeran autogene is an individualized neoantigen therapy given after surgery. According to Associated Press via U.S. News, the product is custom-built for each patient based on the specific genetic mutations found in their surgically removed tumor.

Once administered, the mRNA instructs the patient's body to recognize those unique tumor markers and mount a targeted immune response, while Keytruda works by preventing leftover cancer cells from hiding from the immune system. Moderna CEO Stéphane Bancel noted in a statement that from the start, the company believed mRNA technology could make it possible to develop cancer treatments uniquely matched to each patient's tumor.

Because the immune system requires time to receive the full series of doses and build up a defense, the data revealed a distinct delay before the added benefit appeared. During the first six months of the trial, the risk of recurrence or death was virtually identical between the two groups (a hazard ratio of 0.99), as was the risk of distant metastasis (a hazard ratio of 1.01). However, in a pre-specified analysis looking specifically at patient outcomes after the initial six-month immunization window, the combination therapy reduced the relative risk of recurrence or death by 58% compared to Keytruda alone.

What This Means for Patients and Unanswered Questions

Independent oncology specialists view the Phase 3 milestone as a meaningful step forward for post-surgical melanoma care, though important clinical questions remain open. Karen Knudsen, CEO of the nonprofit Parker Institute for Cancer Immunotherapy, told Scientific American that the findings are "really encouraging," noting that a personalized mRNA cancer therapy of this type was considered "fiction" just 10 years ago because it was thought to be so difficult to accomplish.

At the same time, patients and clinicians must weigh several limitations in the current dataset, including survival confirmation and treatment side effects.

Does the mRNA therapy help patients live longer?

Not yet confirmed. The current results measure whether the cancer returns or spreads, rather than overall survival—the gold-standard measure of whether patients live longer overall. While The Washington Post and Merck note that investigators observed a "favorable trend" in overall survival for the combination group, both Reuters and Scientific American emphasize that the overall survival data are not yet mature. As Knudsen pointed out, researchers are still waiting on longer-term follow-up to answer whether people who received the vaccine lived longer and what their quality of life looked like.

What are the side effects of the combination treatment?

Merck stated that the safety profile of intismeran autogene plus Keytruda was consistent with earlier trials and revealed no new safety signals. According to Fierce Biotech, treatment-related adverse events occurred in 95.8% of patients receiving the combination therapy, compared with 90.0% of patients receiving Keytruda alone. While these figures show that adding the mRNA therapy does not eliminate the substantial side-effect burden associated with cancer immunotherapy, the initial summary rates do not break down how severe each reaction was or which specific symptoms were caused by the vaccine versus Keytruda.

Is this treatment currently available to the public?

No. Intismeran autogene remains an investigational therapy and has not yet been approved by the U.S. Food and Drug Administration or other global health regulators. Merck and Moderna are continuing to track patients in the INTerpath-001 study to gather mature survival data while they begin regulatory discussions.

Sources